Future potential therapies for IBD may target inflammatory foci using PEPT1 ligands such as Lys-Pro-Val, chemically modified PEPT1-transported prodrugs or probiotics that downregulate PEPT1 expression in the small and large intestine [65]. The gene discussed is SLC15A1; the disease is irritable bowel syndrome.